Actigrip Giorno & Notte

Actigrip Giorno & Notte is a prominent pharmaceutical product specifically formulated for the Italian market to manage cold and flu symptoms through a dual day-and-night regimen. The white daytime tablets contain paracetamol and pseudoephedrine to reduce fever and congestion while maintaining alertness, while the blue nighttime tablets combine paracetamol with diphenhydramine to aid rest.

Originally part of the Johnson & Johnson consumer health portfolio, the brand has undergone significant corporate shifts. In 2023, it became part of Kenvue following its spin-off from Johnson & Johnson. More recently, in late 2025, it was announced that Kimberly-Clark would acquire Kenvue, a deal expected to conclude in the latter half of 2026. While the brand is a staple in Italian pharmacies, manufacturing is primarily handled at the Janssen-Cilag facility in Val-de-Reuil, France.